Rate My Professor Paul Welsh

His research focuses on epidemiological analyses of risk factors for cardiovascular disease, diabetes, heart failure, and related conditions using circulating biomarkers including NT-proBNP, high-sensitivity troponin, lipoprotein(a), inflammatory markers, and metabolomic profiles to predict clinical outcomes such as mortality, stroke, and microvascular events. Welsh contributes to major cohorts like UK Biobank, Generation Scotland, Lothian Birth Cohort, and MIDSPAN Family Study, and trials such as DAPA-HF, DiRECT, ADVANCE, TARTAN-HF, EMPRESS-MI, and PRIZE. Key publications include "Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials" (2010), "Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial" (2018), "Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial" (2019), and "Cardiac troponin T and troponin I in the general population: comparing and contrasting their genetic determinants and associations with outcomes" (2019). These highly cited works have enhanced biomarker applications in risk prediction and cardiometabolic patient care.